Study of nitric oxide in patients with chronic hepatitis C genotype 4: Relationship to viremia and response to antiviral therapy

Immunological Investigations

Volumn 39, Issue 6, 2010, Pages 598-610

  Zaki, Maysaa El Sayed ^a   Saudy, Niveen ^a   El Diasty, Amany ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Chronic hepatitis C; Interferon; Nitric oxide; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; NITRATE; NITRIC OXIDE; NITRITE; PEGINTERFERON; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BIOMARKERS, PHARMACOLOGICAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; NITRIC OXIDE; POLYETHYLENE GLYCOLS; RIBAVIRIN; RISK FACTORS; VIRAL LOAD; VIREMIA;

EID: 77954999505     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820131003720710     Document Type: Article

References (36)

1. Aljumah, F., Kanawi, R. Al., Alahdal, A. O., Mayet, A. H., Al-Karawi, A. J., Sbeih, G. (2000). Treatment of chronic hepatitis C genotype IV with interferon-ribavirin combination in Saudi Arabia: a multicentre study. J. Viral Hep. 7(4):287-291.
2. Amaro, M. J., Bartolome, J., Pardo, M., Cotonat, T., Lopez-Farre, A., Carreno, V. (1997). Decreased nitric oxide production in chronic viral hepatitis B and C. J. Med. Virol. 51:326-331
3. Carreño, V. (2006). Occult hepatitis C virus infection: A new form of hepatitis C. World J. Gastroenterol. 21;12(43):6922-6925. (Pubitemid 44834880)
4. Corghi, D. B., Gonçales, N. S., Marques, S. B., Gonçales, Jr. F.L. (2008). Distribution of the human leucocyte antigen class II alleles in Brazilian patients with chronic hepatitis C virus infection. Braz J Med Biol Res. 41(10):884-889.
5. Cramp, M. E., Rossol, S., Chokshi, S., Carucci, P., Williams, R., Naoumov, N. V. (2000). Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118:346-355.
6. Degroote, M. A., Fang, F. C. (1995). NO inhibitions. Antimicrobial properties of nitric oxide. Clin. Infect. Dis. 21:S162-S165.
7. Devin, J. K., Vaughan, D. E., Blevins, L.S. Jr., Chen, Q., Covington, J., Verity, D. K., Young, P. P. (2008). Low-dose growth hormone administration mobilizes endothelial progenitor cells in healthy adults. Growth Horm IGF Res. 18(3):253-263.
8. Dustin, L. B., Rice, C. M. (2007). Flying under the radar: the immunobiology of hepatitis C. Annu. Rev. Immunol. 25:71-99.
9. el-Zayadi, A., Simmonds, P., Dabbous, H., Prescott, L., Selim, O., Ahdy, A. (1996). Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4. J, Viral. Hepat. 3:261-264. (Pubitemid 126733926)
10. Hokaria, A., Zeniya, M., Esumib, H., Ishikawaa, T., Kurasimab, Y., Toda, G. (2005). Role of nitric oxide (NO) in interferon-alpha therapy for hepatitis C. J. Infect. 51:47-53.
11. Kanai, K., Kako, M., Okamoto, H. (1992). HCV genotypes in chronic hepatitis C and response to interferon. Lancet 339:1543.
12. Lai, M. M. (2002). Hepatitis C virus proteins: direct link to hepatic oxidative stress, steatosis, carcinogenesis and more. Gastroenterology 122:568-571.
13. Large, M. K., Kittlesen, D. J., Hahn, Y. S. (1999). Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J. Immunol. 162:931-938.
14. Lee, C. H., Choi, Y. H., Yang, S. H., Lee, C. W., Ha, S. J., Sung, Y.C. (2001). Hepatitis C virus core protein inhibits interleukin 12 and nitric oxide production from activated macrophages. Virology 279:271-279.
15. Lluch, P., Cortina, B., Vila, J. M., Segarra, G., Mauricio, M. D., del Olmo, J. A., Serra, M. A., Lluch, S., Rodrigo, J. M. (2009). Unchanged plasma levels of dimethylarginines and nitric oxide in chronic hepatitis C. Scand. J. Gastroenterol. 4, 224-228.
16. Lyra, A. C., Ramrakhiani, S., Bacon, B. R., Di Bisceglie, A. M. (2004). Infection with hepatitis C virus genotype 4 in the United States. J. Clin. Gastroenterol. 38:68-71.
17. McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M. H., Cort, S., Albrecht, J. K. (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 19; 339(21):1485-1492.
18. Machida, K., Cheng, K. T., Sung, V. M., Lee, K. J., Levine, A. M., Lai, M. M. (2004). Hepatitis C virus infection activates the immunologic (Type II) isoform of nitric oxide synthase and thereby enhances DNA damage and mutations of cellular genes. Virology 78(16): 8835-8843.
19. Machida, K., Cheng, K. T., Sung, V. M., Shimodaira, S., Lindsay, K. L., Levine, A. M., Lai, M. Y., Lai, M. M. (2004). Hepatitis C virus induces a mutator phenotype. Proc. Natl. Acad. Sci. USA 101:4262-4267.
20. Mihm, S., Fayyazi, A., Ramadori, G. (1997). Hepatic expression of inducible nitric oxide synthase transcripts in chronic hepatitis C virus infection: Relation to hepatic viral load and liver injury. Hepatology 26(2):451-458.
21. Nathan, C., Xie, Q.-W. (1994). Regulation of biosynthesis of nitric oxide. J. Biol. Chem. 269:13725-13728.
22. Neuman, M. G., Sha, K., Esguerra, R., Zakhari, S., Winkler, R. E., Hilzenrat, N., Wyse, J., Cooper CL, Seth D, Gorrell MD, Haber PS, McCaughan GW, Leo MA, Lieber CS, Voiculescu M., Buzatu, E., Ionescu, C., Dudas, J., Saile, B., Ramadori, G. (2008). Inflammation and repair in viral hepatitis C. Dig. Dis. Sci. 53(6):1468-1487.
23. Ning, Q., Brown, D., Parodo, J., Cattral, M., Gorczynski, R., Cole, E., Fung, L., Ding, J.W., Liu, M. F., Rotstein, O., Phillips, M. J., Levy, G. (1998). Ribavirin inhibits viral induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J. Immunol. 160:3487-3493.
24. Poynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., Albrecht, J. (1998). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 352(9138):1426-1432.
25. Ohno, O., Mizokami, M., Wu, R. R., Saleh, M. G., Ohba, K., Orito, E., Mukaide, M., Williams, R., Lau, J. Y. (1997). New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J. Clin. Microbiol. 35(1):201-207.
26. Okuda, M., Li, K., Beard, M.R., Showalter, L.A., Scholle, F., Lemon, S. M., Weinman, S. A. (2002). Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122:366-375.
27. Okuda, M., Li, K., Beard, M. R., Showalter, L. A., Scholle, F., Lemon, S. M., Weinman, S. A. (2002). Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122:366-375.
28. Osman, H. G., Gabr, O. M., Lotfy, S., Gabr, S. (2007). Serum levels of bcl-2 and cellular oxidative stress in patients with viral hepatitis. Ind. J. Med. Microbiol. 25(4):323-329.
29. Samuel, C. E. (2001). Antiviral actions of interferons. Clin. Microbiol. Rev. 14(4): 778-809.
30. Sharara, A. I., Perkins, D. J., Misukonis, M. A., Chan, S. U., Dominitz, J. A., Weinberg, J. B. (1997). Interferon (IFN)-alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-alpha in vivo. J. Exp. Med. 186:1495-1502.
31. Shobokshi, O., Serebour, F. R., Skakni, L., Al Jaser, N., Tantawe, A. O., Sabah, A., Dinish, T., Qatani, T., Sandokji, A., Al-Blowi, A., Karawi, M., Al-Kayyal, B., Al-Momen, S., Akbar, H., Ayoola, A., El-Hazmi, M., El-Hazmi, M., Humaida, A., Eissa, H., Al-Quaiz, M., Khawajah, F., Al-Khalifa, M. (2002). Peg-IFN Alfa-2a (40kda) As a monotherapy or in combination with ribavirin significantly improve end of treatment response rate. In: HCV Genotype 4 Chronic Active Hepatitis (CAH) Patients. 53rd AASLD 2002. Boston, MA. Hepatology 36:2.
32. Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., et al. (2009). Genome-wide association of IL28B with response to pegylated interferon-|[alpha]| and ribavirin therapy for chronic hepatitis C. Nature Genetics 41: 1105-1109.
33. Tanaka, Y., Agha, S., Saudy, N., Kurbanov, F., Orito, E., Kato, T., Abo-Zeid, M., Khalaf, M., Miyakawa, Y., Mizokami, M. (2004). Exponential spread of hepatitis C virus genotype 4a in Egypt. J. Mol. Evol. 58(2):191-195. (Pubitemid 38183970)
34. Taylor-Robinson, A. W., Liew, F. Y., Severn, A., Xu, D., McSorley, S. J., Garside, P., Padron, J., Phillips, R. S. (1994). Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells. Eur. J. Immunol. 24:980-984.
35. Thurairajah, P. H., Thorburn, D., Hubscher, S., White, A., Lai, W. K., O'Donnell, K., Mutimer, D. (2007). Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C. Aliment Pharmacol Ther. 25(11):1293-1300.
36. Yee, L. J., Im, K., Wahed, A. S., Bugawan, T., Li, J., Rhodes, S. L., Erlich, H., Rosen, H. R., Liang, T. J., Yang, H. (2009). Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C. Antimicrob. Agents Chemother. 53(2):615-621.